title: Salinomycin encapsulated nanoparticles as a targeting vehicle for glioblastoma cells.
abstract: Salinomycin has been introduced as a novel alternative to traditional anti-cancer drugs. The aim of this study was to test a strategy designed to deliver salinomycin to glioblastoma cells in vitro. Salinomycin-encapsulated polysorbate 80-coated poly(lactic-co-glycolic acid) nanoparticles (P80-SAL-PLGA) were prepared and characterized with respect to particle size, morphology, thermal properties, drug encapsulation efficiency and controlled salinomycin-release behaviour. The in vitro cellular uptake of P80-SAL-PLGA (5 and 10 µM) or uncoated nanoparticles was assessed in T98G human glioblastoma cells, and the cell viability was investigated with respect to anti-growth activities. SAL, which was successfully transported to T98G glioblastoma cells via P80 coated nanoparticles (∼14% within 60 min), greatly decreased (p < 0.01) the cellular viability of T98G cells. Substantial morphological changes were observed in the T98G cells with damaged actin cytoskeleton. Thus, P80-SAL-PLGA nanoparticles induced cell death, suggesting a potential therapeutic role for this salinomycin delivery system in the treatment of human glioblastoma.
authors.affiliation: Department of Biomedical Engineering, Bülent Ecevit University, İncivez, Zonguldak, 67100, Turkey.
authors.forename: R Seda
authors.initials: RS
authors.lastname: Tığlı Aydın
authors.affiliation: Bioengineering Division, Hacettepe University, Beytepe, Ankara, Turkey.
authors.forename: Gökçe
authors.initials: G
authors.lastname: Kaynak
authors.affiliation: Bioengineering Division, Hacettepe University, Beytepe, Ankara, Turkey.|Department of Chemical Engineering, Hacettepe University, Beytepe, Ankara, Turkey.
authors.forename: Menemşe
authors.initials: M
authors.lastname: Gümüşderelioğlu
mesh_terms: D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000494:pharmacology; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry / Q000494:pharmacology; D011100:Polyglycolic Acid / Q000737:chemistry / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011136:Polysorbates / Q000737:chemistry / Q000494:pharmacology; D011714:Pyrans / Q000737:chemistry / Q000494:pharmacology; D000095662:Polyether Polyketides
chemical_list: D003692:Delayed-Action Preparations; D019344:Lactic Acid; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011136:Polysorbates; D011714:Pyrans; C010327:salinomycin; D000095662:Polyether Polyketides
keywords: PLGA; glioblastoma; nanoparticle; polysorbate 80; salinomycin; targeting